ICP 033
Alternative Names: ICP-033Latest Information Update: 28 May 2025
At a glance
- Originator InnoCare Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Discoidin domain receptor 1 antagonists; Protein kinase inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Colorectal cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Ovarian-cancer in China (PO)
- 28 May 2025 No recent reports of development identified for preclinical development in Prostate-cancer in China (PO)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (PO)